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Abstract
Vitiligo is an acquired and progressive hypomelanotic disease that manifests as circumscribed depigmented patches on the skin. The aetiology
of vitiligo remains unclear, but recent experimental data underline the interactions between melanocytes and other typical skin cells, particularly
keratinocytes. Our previous results indicate that keratinocytes from perilesional skin show the features of damaged cells. Sirtuins (silent mating
type information regulation 2 homolog) 1, well-known modulators of lifespan in many species, have a role in gene repression, metabolic
control, apoptosis and cell survival, DNA repair, development, inflammation, neuroprotection and healthy ageing. In the literature there is no evi-
dence for SIRT1 signalling in vitiligo and its possible involvement in disease progression. Here, biopsies were taken from the perilesional skin
of 16 patients suffering from non-segmental vitiligo and SIRT1 signalling was investigated in these cells. For the first time, a new SIRT1/Akt,
also known as Protein Kinase B (PKB)/mitogen-activated protein kinase (MAPK) signalling has been revealed in vitiligo. SIRT1 regulates MAPK
pathway via Akt-apoptosis signal-regulating kinase-1 and down-regulates pro-apoptotic molecules, leading to decreased oxidative stress and
apoptotic cell death in perilesional vitiligo keratinocytes. We therefore propose SIRT1 activation as a novel way of protecting perilesional vitiligo
keratinocytes from damage.
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Introduction
Vitiligo appears as an enigmatic spectrum of depigmenting disorders
affecting melanocytes to a different extent [1]. The aetiology of vitiligo
remains unclear, but oxidative stress and the accumulation of free
radicals have been proposed as important pathogenic mechanisms
[2, 3]. Recent experimental data underline the interactions between
melanocytes and other typical skin cells, particularly keratinocytes.
Previous results from our laboratory indicate that keratinocytes from
perilesional skin show significant biochemical alterations, such as
increased production of reactive oxygen species (ROS), lipoperoxida-
tion and mitochondrial alterations, while apoptotic markers are pri-
marily observed in keratinocytes from perilesional skin rather than in
lesional or healthy skin [4]. This led us to hypothesize that perilesion-
al vitiligo skin may represent the substrate where melanocyte death is
initiated, with a substantial role played by keratinocytes in the devel-
opment of disease.
Resveratrol (Resv) is a polyphenolic antioxidant containing two
phenyl rings separated by a methylene bridge that is produced natu-
rally in red grapes, berries and peanuts. Resveratrol can reduce the
risk of several diseases and plays an important role in inflammation
and tumour suppression [5]. Recent research has demonstrated that
Resv activates the silent information regulator 2 (Sir2) family, and that
the protective effects of Resv are mostly dependent on SIRT1 [6].
The members of the mammalian Sir2 family, or sirtuins, a cluster
of highly conserved proteins eliciting nicotinamide adenine dinucleo-
tide (NAD)-dependent histone deacetylase activity, have been shown
to target histone and non-histone substrates, including enzymes,
transcription regulators, tumour suppressors, cell signalling proteins
and DNA repair proteins [7].
The requirement of NAD+ for the catalytic activity of sirtuins sug-
gests they may have evolved as sensors of cellular energy and redox
status. Several lines of evidence indeed point to a role for sirtuins in
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the response to changes in NAD+, Nicotinamide adenine dinucleotide
and/or nicotinamide concentrations, as brought about by metabolic
pathways [8, 9]. To date, seven human sirtuins have been identified
and named SIRT1-7 [10]. All these possess an NAD+-dependent cata-
lytic core domain, which can function as an NAD+-dependent deacety-
lase (DAC) and/or mono-ADP-ribosyl transferase.
SIRT1 is the most extensively studied human sirtuin: indeed, 12
substrates with possible roles in cell processes ranging from cell sur-
vival to apoptotic signalling have been identified.
In addition to histones, SIRT1 also deacetylates several other pro-
teins and emerges as a regulator of cellular mechanisms involved in
stress responses.
Expression of all seven sirtuins has been demonstrated in human
epidermal and dermal cells [11]. Sirtuins are involved in cellular path-
ways related to skin structure and function including photoageing,
inflammation, cancer and cutaneous infections [12]. Two key media-
tors of skin damage, UV radiation and H2O2, down-regulate SIRT1
expression in cultured skin keratinocytes [13]. Resv activates SIRT1
in these UV-exposed keratinocytes, resulting in a decrease in p53-
mediated apoptosis [13, 14]. Conversely, pre-treatment with SIRT1
inhibitors sirtinol or nicotinamide promotes UV-induced, p53-medi-
ated apoptosis [13]. Additional research has demonstrated decreased
SIRT1, 3 and 7 expression in UVB-irradiated adult donor skin samples
and cultured skin [15]. Decreased sirtuin expression was not identi-
fied in chronologically, non-sun exposed aged skin; however, sug-
gesting that these sirtuins may be potential targets to prevent
photoageing but not chronological ageing [15]. Therefore, upregula-
tion of SIRT1, 3 and/or 7 are potential therapeutic targets to improve
skin ageing and appearance [15].
Signs of oxidative stress and apoptosis in keratinocytes from per-
ilesional vitiligo skin were found in our previous studies. In particular,
we have observed high levels of activated p38, NF-kB p65 subunit,
Smac/DIABLO and p53 [16]. On the basis of these data, we decided
to investigate the role of SIRT1 signalling in these cells.
In the literature there is no evidence for SIRT1 signalling in vitiligo
and its possible involvement in disease progression. Here we investi-
gated a possible protective role played by this protein in keratinocytes
from perilesional vitiligo skin.
Materials and methods
Keratinocyte isolation and cell culture
Punch-biopsies of 6 mm were taken from lesional, perilesional and
healthy skin of 16 patients affected by non-segmental vitiligo all of
which had a similar clinical history with respect to lesion extension
and duration of the disease. All biopsies were taken from sun-unex-
posed areas. Lesional, perilesional and healthy skin is defined as clini-
cally affected skin, skin along the edge of the white patch and
clinically unaffected, normally pigmented skin respectively. Only
patients with stable vitiligo were included in this study. The use of sta-
ble case of vitiligo to obtain skin biopsies has several technical advan-
tages in the setting up and maintenance of primary cell cultures.
Furthermore, it has enabled us to achieve a higher degree of reproduc-
ibility in the experiments. None of the patients underwent any kind of
treatment (neither systemic nor topical) 6 months before biopsies were
obtained. None of the patients we selected had any autoimmune dis-
ease in addition to vitiligo, nor did they have auto-antibodies against
any organs. The clinical information of each patient is summarized in
Table 1. Written permission was obtained from all patients. The study
was conducted in accordance with the Declaration of Helsinki and was
approved by the local institutional review board. Keratinocytes were
isolated according to a previously published method [2]. The expres-
sion of cytokeratins was evaluated at each passage in vitro by a posi-
tive staining to pan-cytokeratin antibody (data not shown) to assess
the maintenance of the same immunophenotype. At the first passage,
the absence of vimentin expression induced us to exclude the pres-
ence of any fibroblasts.
Cell treatment
To investigate the effect of SIRT1 activation, keratinocytes from perile-
sional vitiligo skin were grown for 24 hrs in the presence of 20 lM
Resv. To see whether the effects of Resv were because of its antioxi-
dant activity only, experiments were also performed in the same cells
treated with 15 lM Trolox, a concentration required to obtain the same
antioxidant capacity of 20 lM Resv.
Trolox (6-hydroxy- 2, 5, 7, 8-tetramethylchromane-2-carboxylic acid)
is a water-soluble analogue of the free radical scavenger a-tocopherol.
Trolox has advantages over a-tocopherol, which is lipid soluble because
it can be incorporated in both the water and the lipid compartments of
cells [17–19].
To check possible toxic effects of these compounds, untreated cells
were also considered and maintained in complete culture medium for the
same time. In another set of experiments, cells were treated with 10 lM
SB203580 (p38 kinase inhibitor), 10 lM SP600125 [JNK (c-Jun N-term-
inal kinase) inhibitor], 10 lM PD98059 (MEK inhibitor) [20], 1 lM 6-
Chloro-2,3,4,9-tetrahydro-1H-Carbazole-1-carboxamide (specific SIRT1
inhibitor) for 1 hr. All reagents were reconstituted in dimethyl sulfoxide
following the manufacturer’s instructions. All reagents were purchased
from Sigma-Aldrich (Milan, Italy) and were of the highest purity available.
Preparation of cell homogenates
Keratinocytes from perilesional vitiligo skin (1 9 106) were washed
twice with PBS, trypsinized, centrifuged and then resuspended in
100 ml of lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl
pH8, 137 mM NaCl, 10% (v/v) glycerol, 2 mM ethylenediaminetetraace-
tic acid (EDTA) and 6 M urea supplemented with 0.2 mM PMSF, as well
as 10 mg/ml leupeptin and aprotinin. To obtain cell homogenates, sam-
ples, after three freeze–thaw cycles, were twice sonicated in ice for
5 sec. and then centrifuged at 14,000 9 g for 10 min. at 4°C. The
supernatant was then collected. The protein concentration was deter-
mined according to the Bradford method [21].
Determination of cellular SIRT1 activity
Cellular SIRT1 activity was determined according to the method
described by Fulco et al. [22] with some modifications. Cell extracts
were obtained by using a lysis buffer (50 mM Tris–HCl pH 8, 125 mM
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NaCl, 1 mM DTT, 5 mM MgCl2, 1 mM EDTA, 10% glycerol and 0.1%
NP40 supplemented with 1 mM PMSF and protease inhibitors mix) and
SIRT1 activities were determined by SIRT1 Direct Fluorescent Screening
Assay Kit (Cayman, Ann Arbor, MI, USA). A volume of 25 ll of Assay
buffer (50 mM Tris–HCl, pH 8.0, containing 137 mM NaCl, 2.7 mM Kcl,
and 1 mM MgCl2), 5 ll of extracts and 15 ll of substrate solution was
added to all wells. The plate was incubated on a shaker for 45 min. A
quantity of 50 ll of Stop/Development solution was added to each well
and incubated for 30 min. at room temperature. The fluorescence of the
plate was then determined with a Perkin-Elmer LS 55 luminescence
spectrometer with an excitation wavelength of 360 nm and an emission
wavelength of 460 nm.
Western blot analysis of p-ASK1
To assess the levels of p-apoptosis signal-regulating kinase-1 (ASK1)
equal amounts of total homogenate (50 lg) were diluted in Laemmli
sample buffer, boiled for 5 min. and separated on pre-cast 4–12%
SDS-PAGE gels (Criterion XT, Bio-Rad Laboratories, Milan, Italy). Pro-
teins were blotted onto polyvinylidene difluoride (PVDF) Hybond
membranes, which were then incubated overnight at 4°C with (rabbit)
anti-p-ASK1 pSer83 antibody (GenWay Biotech Inc.; rabbit, San Diego,
CA, USA) anti-ASK1 (Santa Cruz Biotechnology Inc., Dallas, TX, USA).
After washing, membranes were incubated with peroxidase-conjugated
secondary antibodies for 1 hr. Immunolabelled bands were detected
with a SuperSignal West Dura (Pierce, Rockford, IL, USA) and quanti-
fied with the aforementioned software for image analysis.
Immunoprecipitations and immunoblot analysis
For immunoprecipitation, whole cell lysate were pre-cleared with Protein
A/G plus (Santa Cruz Biotechnology Inc.) for 30 min at 4°C. Beads were
pelleted at 1000 9 g for 30 s and pre-cleared supernatants were incu-
bated with 15 lg of primary antibody-agarose conjugates at 4°C over-
night on a rotator. When agarose or a gel conjugate was unavailable,
lysates were incubated with anti-Akt antibody (Santa Cruz Biotechnology
Inc.) for 2 hrs at 4°C and then overnight along with Protein A/G plus
beads to collect the immune complexes. Beads were collected by centri-
fugation, washed several times with RIPA buffer, one wash with PBS,
and resuspended in SDS-PAGE sample loading buffer. Immune com-
plexes and 80 lg of proteins were resolved by SDS-PAGE. Proteins
were blotted onto PVDF Hybond membranes, which were then incu-
bated overnight at 4°C with (mouse) anti-Akt antibody (mouse) anti-
pAkt (mouse) anti-Ac-lysine (Santa Cruz Biotechnology Inc.). After
washing, membranes were incubated with peroxidase-conjugated sec-
ondary antibodies for 1 hr. Immunolabelled bands were detected with a
SuperSignal West Dura (Pierce).
Determination of intracellular ROS and
mitochondrial superoxide
Keratinocytes from perilesional vitiligo skin were seeded on glass cover
slips and loaded with the mitochondrial superoxide-specific fluorescent
probe MitoSOX (3 lM) and H2DCFDA (2.5 lM; Invitrogen, Carlsbad,
Table 1 Clinical data of vitiligo patients
Patients Age Clinical type of vitiligo Age of onset/Stability of vitiligo (years) Biopsy site
M1 43 NS generalized 19/7 Trunk
M2 51 NS generalized 6/8.5 Trunk
M3 47 NS generalized 11/10 Abdomen
M4 39 NS generalized 5/8 Pubis
M5 52 NS generalized 25/7 Abdomen
M6 45 NS localized 21/10 Trunk
M7 48 NS generalized 22/9 Trunk
M8 52 NS generalized 23/8 Abdomen
F1 44 NS generalized 31/8 Abdomen
F2 38 NS generalized 20/7.5 Trunk
F3 49 NS generalized 13/9 Trunk
F4 42 NS generalized 33/8 Pubis
F5 50 NS generalized 27/7 Abdomen
F6 46 NS localized 18/9.5 Trunk
F7 44 NS generalized 28/10 Abdomen
F8 51 NS generalized 12/7 Trunk
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CA, USA) – dissolved in 0.1% DMSO and Pluronic acid F-127 (0.01%
w/v) – which was added to cell culture media for 15 min. at 37°C. Cells
were fixed in 2.0% buffered paraformaldehyde for 10 min. at room tem-
perature and the H2DCFDA and MitoSOX fluorescence analysed with a
Leica TCS SP5 confocal scanning microscope (Mannheim, Germany)
equipped with an argon laser for fluorescence analysis. A series of opti-
cal sections (1024 9 1024 pixels) 1.0 lm in thickness was taken
through the cell depth at intervals of 0.5 lm with a Leica 209 objective
and then projected as a single composite image by superimposition.
Mitochondrial superoxide and ROS generation were also monitored by
flow cytometry: single-cell suspensions were incubated with MitoSOX
(0.5 lM) and H2DCFDA (1 lM; Invitrogen) for 15 min. at 37°C and
immediately analysed with a FACSCanto flow cytometer (Becton-
Dickinson, San Jose, CA, USA).
Total antioxidant capacity (TAC)
Intracellular TAC, which accounts for ROS scavengers, was measured in
cell lysates by chemiluminescent assay with the photoprotein Pholasin
(Abel Antioxidant Test Kit; Knight Scientific Limited, Plymouth, UK), fol-
lowing the manufacturer’s instructions. Protein content in the soluble
fraction was measured with the Bradford method [21] and results calcu-
lated with an L-ascorbic acidbased standard curve.
Evaluation of lipid peroxidation
To assess the rate of lipid peroxidation, isoprostane levels were mea-
sured in cell lysates with the 8-isoprostane EIA kit (Cayman Chemical
Co.), following the manufacturer’s instructions. Lipid peroxidation was
also investigated by confocal scanning microscopy with BODIPY, a fluo-
rescent probe that is intrinsically lipophilic and thus mimics the proper-
ties of natural lipids [23]. BODIPY 581/591 C11 acts as a fluorescent
lipid peroxidation reporter that shifts its fluorescence from red to green
in the presence of oxidizing agents. Briefly, cells were cultured on glass
coverslips and loaded with dye by adding the fluorescent probe BODIPY,
dissolved in 0.1% DMSO (5 mM final concentration), to the cell culture
media for 30 min. at 37°C. The cells were fixed in 2.0% buffered para-
formaldehyde for 10 min. at room temperature and the BODIPY fluores-
cence analysed (at an excitation wavelength of 581 nm) with a confocal
Leica TCS SP5 scanning microscope equipped with an argon laser
source for fluorescence measurements. A series of optical sections
(1024 9 1024 pixels) 1.0 lm in thickness was taken through the cell
depth at intervals of 0.5 lm with a Leica Plan Apo 639 oil immersion
objective and then projected as a single composite image by superimpo-
sition. Moreover, lipid peroxidation was quantified by flow cytometry.
Single-cell suspensions were washed twice with PBS and incubated, in
the dark, for 30 min. at 37°C with BODIPY 581/591 (2 mM) in DMEM.
After labelling, cells were washed and resuspended in PBS and analysed
with a FACSCanto flow cytometer (Becton-Dickinson).
Mitochondrial number
Mitochondrial number was determined with MitoTracker Deep Red 633
(Invitrogen), which was used to stain mitochondria, and confocal
microscopy used to visualize individual mitochondria. Briefly, cells were
seeded on glass cover slips and loaded with MitoTracker Deep Red 633
fluorescent probe (0.5 lM) – dissolved in 0.1% DMSO and Pluronic acid
F-127 (0.01% w/v) – which was added to cell culture media for 20 min.
at 37°C. Cells were fixed in 2.0% buffered paraformaldehyde for 10 min.
at room temperature and red fluorescence analysed (at an excitation
wavelength of 633 nm) with a Leica TCS SP5 confocal scanning micro-
scope equipped with an argon laser source for fluorescence analysis.
Mitochondrial number was also monitored by flow cytometry. Single-cell
suspensions were incubated with MitoTracker Deep Red 633 (200 nM)
for 20 min. at 37°C and immediately analysed by flow cytometry.
Mitochondrial permeability transition pore
opening
Mitochondrial permeability was analysed with the fluorescent calcein-AM
probe, according to the method described by Petronilli et al. [24], albeit
with minor modifications. Calcein-AM freely enters cells and emits fluo-
rescence upon de-esterification. Co-loading of cells with cobalt chloride
quenches cell fluorescence except in mitochondria. This is because cobalt
cannot cross mitochondrial membranes (living cells). During mitochon-
drial permeability transition pore opening (mPTP), cobalt can enter mito-
chondria and is able to quench calcein fluorescence (apoptotic cells).
Thus, decreased mitochondrial calcein fluorescence can be considered a
measure of the extent of mPTP induction. Briefly, single-cell suspensions
were incubated with the fluorescent probes calcein-AM (Invitrogen;
3 lM) and cobalt chloride (1 mM) for 20 min. at 37°C, washed twice with
PBS and analysed with a FACSCanto flow cytometer (Becton-Dickinson).
Mitochondrial membrane potential
Mitochondrial membrane potential was assessed with tetramethylrhod-
amine, methyl ester, perchlorate (TMRM). TMRM is a lipophilic potentio-
metric dye that partitions between the mitochondria and cytosol in
proportion to Dw by virtue of its positive charge. At low concentrations,
the fluorescence intensity is a simple function of dye concentration,
which is in turn a direct function of mitochondrial potential. Therefore,
the accumulation of dye in mitochondria and the intensity of the signal
is a direct function of mitochondrial potential. For confocal microscope
analysis, cells were cultured on glass cover slips and loaded with dye by
adding the fluorescent probe TMRM, dissolved in 0.1% DMSO (100 nM
final concentration), to the cell culture media for 20 min. at 37°C. The
cells were fixed in 2.0% buffered paraformaldehyde for 10 min. at room
temperature and the TMRM fluorescence analysed (at an excitation
wavelength of 543 nm) with a confocal Leica TCS SP5 scanning micro-
scope equipped with a helium-neon laser source for fluorescence mea-
surements. Mitochondrial membrane potential was also quantified by
flow cytometry. Single-cell suspensions were washed twice with PBS
and incubated, in the dark, for 20 min. at 37°C with TMRM (100 nM) in
DMEM. After labelling, cells were washed and resuspended in PBS and
analysed with a FACSCanto flow cytometer (Becton-Dickinson).
Assessment of caspase activity by flow cytometry
Caspase-3 and caspase-9 activity was analysed by flow cytometry. In
brief, single-cell suspensions were incubated with FAM-FLICATM Caspases
solution (Caspase FLICA kit FAM-DEVD-FMK) for 1 hr at 37°C, washed
twice with PBS and analysed with a FACSCanto flow cytometer (Becton-
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Dickinson). In another set of experiments, designed to determine the
relative importance of ERK, p38 and JNK signalling pathways, cells were
treated with 10 lM SP600125 (specific JNK inhibitor), 10 lM PD98059
(MEK inhibitor) or 1 lM SIRT1 inhibitor for 1 hr prior to hypoxia.
SIRT1 RNA interference (RNAi) experiments
siRNA for SIRT1 (sc-40986) was purchased from Santa Cruz Biotech-
nology. Keratinocytes from healthy vitiligo skin (obtained from patients
M1, M2, M5, M8 and F2, F3, F5, F7 as reported in Table 1) were cul-
tured in complete medium that did not contain antibiotics for 2 days.
Cells were seeded into a six-well plate and cultured to 60–70% conflu-
ence the day before the RNAi experiment when 8 ll of LipofectamineTM
LTX together 3 ll PLUSTM Reagent (Invitrogen, Indianapolis, IN, USA)
was diluted in 90 ll of culture medium. Then, 12 ll SIRT1 siRNA was
mixed with medium containing Lipofectamine together with PLUS
reagent and incubated for 30 min. at room temperature for complex
formation. Finally, the complex was added to the cells with the final
SIRT1 siRNA concentration of 100 nM. SIRT1 protein expression was
determined by Western blot after 48 hrs (Fig. 6A). To evaluate the pos-
sible involvement of SIRT1 in oxidative-mediated damage of vitiligo
keratinocytes, untreated and SIRT1 RNAi-treated keratinocytes from
healthy vitiligo skin were challenged for 3 hrs with 500 lM H2O2. ROS
production, lipid peroxidation, caspase-3 activity and mitochondrial
membrane polarization were measured by flow cytometry.
Assessment of MAPK activity by flow cytometry
Flow cytometry is performed with a FACSCanto flow cytometer (Becton-
Dickinson) and analysis is performed with FACSDiva software. Cells are
fixed and permeabilized with the BD Cytofix/Cytoperm buffer (Becton-
Dickinson) following the manufacturer’s instructions. Anti-Phosphohy-
phen;SAPK/JNK (Thr183/Tyr185) (G9) Mouse mAb (PE Conjugate),
anti-Phospho-p38 mitogen-activated protein kinase (MAPK; Thr180/
Tyr182) (28B10) Mouse mAb (Alexa Fluor 488 Conjugate) and anti-
Phosphohyphen;p44/42 MAPK (Erk1/2) (T hr202/Tyr204) (D13.14.4E)
XP Rabbit mAb (Alexa Fluor 488 Conjugate) were used at 1:50
dilution with 1 hr at room temperature incubation according to manu-
facturer’s instructions.
Statistical analysis
All data are expressed as mean  SD. Comparisons between different
groups were carried out with the one-way ANOVA followed by Bonferroni
t-test. A P < 0.05 was accepted as statistically significant.
Results
SIRT1 activity in keratinocytes from healthy,
lesional and perilesional vitiligo skin
As a preliminary experiment we evaluated the activity of SIRT1 in
keratinocytes from healthy, lesional and perilesional skin (Fig. 1A).
Compared to keratinocytes from healthy and lesional vitiligo skin, per-
ilesional cells exhibited a marked decrease (37% versus healthy
skin, P < 0.001) in SIRT1 activity. Lesional cells showed only a mild
decrease in SIRT1 activity respect to healthy skin from vitiligo
patients (NS versus healthy skin).
Following this, all experiments were performed only in perilesional
cells from vitiligo patients where we already reported [4, 16] the
A
B
C
Fig. 1 (A) SIRT1 activity in keratinocytes from healthy, perilesional and
lesional vitiligo skin. *Significant difference (P ≤ 0.05) versus keratino-
cytes from healthy skins. (B) SIRT1 activity in keratinocytes from perile-
sional vitiligo skin after 24 hrs of incubation with different
concentrations of Resveratrol (Resv). (C) SIRT1 activity in keratinocytes
from perilesional vitiligo skin in the presence of 20 lM Resveratrol
(Resv), 15 lM Trolox or 20 lM Resveratrol+1 lM SIRT1 inhibitor
(Resv+SIRT1i). The reported values (means  SD) are representative
of four independent experiments, each performed in triplicate. *Signifi-
cant difference (P ≤ 0.05) versus untreated perilesional keratinocytes.
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presence of oxidative stress and apoptosis markers exclusively in
keratinocytes from perilesional vitiligo skin.
Dose-dependent effects of Resv on SIRT1 activity
As a preliminary experiment aimed at evaluating the effect of Resv on
SIRT1 activity, a dose-dependent test was carried out in perilesional
cells in the presence of increasing Resv concentrations (Fig. 1B).
Keratinocytes from perilesional vitiligo skin were exposed to Resv
concentrations ranging from 2.5 lM to 80 lM. Twenty-four hour
treatment with 20 lM Resv stimulated a fourfold increase in SIRT1
activity and this Resv concentration was used for all other experi-
ments.
SIRT1 activity in keratinocytes from perilesional
vitiligo skin
The effect of Resv, Trolox and Resv+SIRT1i on SIRT1 activity was
investigated. As shown in Figure 1C, pre-treating with Resv up-regu-
lated SIRT1 expression (fourfold increase versus untreated keratino-
cytes, P < 0.05); a pre-treatment with 15 lM Trolox did not induce a
similar effect (NS versus untreated keratinocytes, P < 0.05). How-
ever, a significant decrease in SIRT1 activity was observed upon addi-
tion of a SIRT1 inhibitor to Resv-pre-treated cells (P < 0.05 versus
untreated keratinocytes).
Oxidative stress and SIRT1 activation in
keratinocytes from perilesional vitiligo skin
To investigate the effect of SIRT1 activation, keratinocytes from per-
ilesional vitiligo skin were grown for 24 hrs in the presence of 20 lM
Resv. To see whether the effects of Resv were merely because of its
antioxidant activity, experiments were also performed in keratinocytes
from perilesional vitiligo skin treated with 15 lM Trolox, the concen-
tration which displayed in vitro the same antioxidant capacity of
20 lM Resv (data not shown). Keratinocytes treated with Resv and
Trolox showed significantly higher TAC with respect to untreated
cells; treatment with Resv caused a significant increase in cellular
TAC, more so than Trolox (P < 0.05 versus Trolox-treated keratino-
cytes), suggesting that Resv-induced SIRT1 activation up-regulate
different antioxidant pathways in response to oxidative stress com-
pared to Trolox. The concentration of 8-isoprostanes was also much
lower in Resv-treated cells compared to Trolox-treated cells
(P < 0.05 versus Trolox-treated keratinocytes; Fig. 2). Lipoperoxida-
tion was also monitored by flow cytometry and confocal microscopy
analysis performed with the fluorescent probe BODIPY and similar
results were obtained (Fig. 3).
Reactive oxygen species production was investigated by flow
cytometry and confocal microscopy analysis performed with the fluo-
rescent probe H2DCFDA (Fig. 3). Resv- and Trolox-treated keratinocytes
were characterized by less marked fluorescence, demonstrating a
strong protective effect exerted by these compounds against ROS.
Similar results were obtained evaluating mitochondrial superoxide
production by flow cytometry and confocal microscope analysis
(Fig. 4). Resv again proved to be more protective than Trolox.
SIRT1 activation protects keratinocytes from
perilesional vitiligo skin from mitochondrial
damage and apoptosis
To ascertain whether SIRT1 activation can protect against apoptotic
cell death, we analysed mitochondrial membrane polarization, the
mitochondrial permeability transition pore opening and caspase acti-
vation. Figure 4 shows confocal microscope analysis of mitochon-
drial superoxide production, which appears strongly enhanced in
untreated perilesional cells but not in antioxidant-treated cells. Mito-
chondrial membrane polarization, which was assessed by confocal
microscopy and flow cytometry (Fig. 4), was found to be impaired
in untreated perilesional keratinocytes. SIRT1 activation effectively
restored mitochondrial membrane polarization. Trolox treatment
showed similar effects, though to a lesser extent. To further confirm
these data, mitochondrial permeability transition pore opening was
analysed by flow cytometry (Fig. 4): Resv-induced SIRT1 activation
again proved to be more protective compared to Trolox (Fig. 4).
Treating keratinocytes from perilesional vitiligo skin with both Resv
and a SIRT-1 inhibitor did not cause any significant change com-
pared to untreated cells.
Mitochondrial number can influence experiments where mito-
chondrial function is investigated; we therefore counted the number
of mitochondria in Resv-treated or non-treated keratinocytes from
Fig. 2 Evaluation of total antioxidant capacity (TAC) and 8-isoprostanes
in keratinocytes from perilesional vitiligo skin in the presence of Resve-
ratrol (Resv), Trolox or Resveratrol+SIRT1 inhibitor (Resv+SIRT1i). The
reported values (means  SD) are representative of four independent
experiments, each performed in triplicate. *Significant difference
(P ≤ 0.05) versus untreated perilesional keratinocytes.
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perilesional vitiligo skin to ensure that increased mitochondrial func-
tion was not because of a mere numeric increase in mitochondria. In
our keratinocytes from perilesional vitiligo skin, no significant
increase in mitochondrial number, compared to untreated cells, upon
Resv treatment was evident (data not shown). Therefore, changes in
mitochondrial function and cell viability are not because of changes in
mitochondrial number.
We measured caspase-3, -8 and -9 activities to confirm that
apoptosis occurs under our experimental conditions. This,
together with the finding that Resv triggers SIRT1 activation,
suggests that Resv may exert its anti-apoptotic effect in a
SIRT1-dependent manner. As shown in our previous studies [4,
16] a marked caspase-3, -8 and -9 activity, which plays a central
role in apoptosis, was observed in keratinocytes from perilesional
vitiligo skin and this increase was reversed by Resv pre-treat-
ment. Treatment with Trolox, albeit to a lesser extent, signifi-
cantly reduced apoptosis. In any case, a significant difference
(P < 0.05) was observed between Resv and Trolox treatments,
both for caspase-3, -8 and -9. A significant increase in caspase-
3, -8 and -9 activity in the presence of SIRT-1 inhibitor (1 lM
6-Chloro-2,3,4,9-tetrahydro-1H-Carbazole-1-carboxamide) was also
evident (Fig. 5).
SIRT1 siRNA-treatment of keratinocytes from
healthy vitiligo skin
In untreated keratinocytes from perilesional vitiligo skin and in kerati-
nocytes from perilesional vitiligo skin after 48 hrs treatment of SIRT1
siRNA 100 nM, SIRT1 protein expression was determined by Western
A
B
Fig. 3 (A) Confocal microscope analysis
and (B) flow cytometry analysis of reac-
tive oxygen species production (63 9
magnification) and lipoperoxidation (63 9
magnification) in keratinocytes from per-
ilesional vitiligo skin in the presence of
Resveratrol (Resv), Trolox or Resvera-
trol+SIRT1 inhibitor (Resv+SIRT1i). The
reported values (means  SD) are repre-
sentative of five independent experiments,
each performed in triplicate. *Significant
difference (P ≤ 0.05) versus untreated
perilesional keratinocytes.
ª 2013 The Authors.
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Fig. 4 (A) Confocal microscope analysis of
mitochondrial superoxide production and
mitochondrial depolarization (63 9 mag-
nification) in keratinocytes from perile-
sional vitiligo skin in the presence of
Resveratrol (Resv), Trolox or Resvera-
trol+SIRT1 inhibitor (Resv+SIRT1i). (B)
Mitochondrial superoxide production,
mitochondrial depolarization and mito-
chondrial permeability transition pore
opening measured by flow cytometry in
keratinocytes from perilesional vitiligo skin
in the presence of Resveratrol (Resv),
Trolox or Resveratrol+SIRT1 inhibitor
(Resv+SIRT1i). The reported values
(means  SD) are representative of five
independent experiments, each performed
in triplicate. *Significant difference
(P ≤ 0.05) versus untreated perilesional
keratinocytes.
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blot analysis to demonstrate the effective knockdown of SIRT-1
(Fig. 6A).
To shed light on the possible role of SIRT1 in oxidative-mediated
damage in vitiligo keratinocytes, ROS production, lipid peroxidation,
caspase-3 activity and mitochondrial membrane polarization were
measured in keratinocytes from healthy vitiligo skin. These parame-
ters were assessed in untreated and in SIRT1 siRNA-treated cells,
challenged or not with H2O2 (500 lM for 3 hrs). In the absence of
H2O2 challenge, the biochemical alterations displayed by SIRT1 siR-
NA-treated keratinocytes did not differ from unchallenged keratino-
cytes (Fig. 6B) in agreement with our recent findings obtained in a
different cellular model [25]. The alterations of the above parameters
were similar to those observed in keratinocytes from perilesional viti-
ligo skin when SIRT1 siRNA-treated keratinocytes were challenged
with H2O2 (Fig. 6). This finding suggests that SIRT1 is a possible
mediator of keratinocyte damage.
MAPK pathways are affected by Resv-induced
SIRT1 activation in keratinocytes from
perilesional vitiligo skin
In our previous study, we demonstrated that keratinocytes from per-
ilesional vitiligo skin showed signs of oxidative stress and apoptosis.
In particular, we underlined the central role of MAPK pathways in
inducing cell damage and apoptosis [4, 16]. Here, we examined p38,
ERK and JNK activation in response to Resv-induced SIRT1 activa-
tion.
Figure 7 shows levels of ERK phosphorylation, whose anti-apop-
totic effect is well documented. SIRT1 activation strongly increases
ERK phosphorylation (+107% versus untreated keratinocytes,
P < 0.05) whereas treatment with Trolox does not lead to a similar
reduction in ERK phosphorylation. On the contrary, treatment with
Resv and SIRT-1 inhibitor causes a significant reduction in ERK phos-
phorylation (23% versus untreated keratinocytes, P < 0.05). In this
study, we also investigated for the first time the role of JNK activation
in keratinocytes from perilesional vitiligo skin. SIRT1 activation by
Resv strongly reduced JNK phosphorylation (46% versus untreated
keratinocytes, P < 0.05), whereas Trolox treatment showed similar
effects, even though to a lesser extent. Treatment with Resv and
SIRT-1 inhibitor lead to an increase in JNK phosphorylation (+26%
versus untreated keratinocytes, P < 0.05), demonstrating a role of
SIRT1 in JNK pathways.
As previously demonstrated [16], p38 plays a prominent role in
perilesional keratinocyte apoptosis via NF-kB and p53 activation. As
already observed, SIRT1 activation significantly reduces p38 phos-
phorylation (74% versus untreated keratinocytes, P < 0.05),
whereas Trolox treatment did not lead to a similar reduction in p38
phosphorylation (46% versus untreated keratinocytes, P < 0.05).
When SIRT1 inhibitor was used with Resv, a dramatic increase in p38
phosphorylation (+60% versus untreated keratinocytes, P < 0.05)
was shown. To further investigate the molecular pathways underlying
the protective role of SIRT1 activation seen in keratinocytes from per-
ilesional vitiligo skin, we analysed caspase-3 activity in the presence
of specific MAPK inhibitors.
As shown in Figure 8, in the presence of p38 or JNK inhibitor
(p38i or JNKi respectively), levels of apoptosis significantly decreased
(P < 0.05 versus untreated keratinocytes), suggesting the involve-
ment of these pathways in keratinocyte apoptosis. Interestingly,
untreated keratinocytes displayed the greatest caspase-3 activity in
the presence of ERK inhibitor, suggesting a prominent role for ERK in
protection against apoptotic cell death.
When Resv was added along with these inhibitors, caspase-3
activity further decreased (P < 0.05 versus untreated keratinocytes).
The presence of SIRT1 inhibitor together with p38i or JNKi triggered
an increase in caspase-3 activity. Simultaneous treatment with the
three inhibitors did not protect against cell death (data not shown).
SIRT1 deacetylates Akt and inhibits ASK1
activation
It has been shown that SIRT1 activates Akt, which in turn can
phosphorylate ASK1 at Ser-83 to maintain ASK1 in an inactive form
[25]. Akt immunoprecipitates from perilesional keratinocytes indi-
cated that phosphorylation of Akt was enhanced in Resv-treated
cells, a finding that was associated with Akt deacetylation, indicat-
ing that SIRT1 deacetylates and activates Akt (Fig. 9A). When
SIRT1 inhibitor was used, deacetylation and phosphorylation of Akt
decreased to the levels observed in untreated keratinocytes, dem-
onstrating that SIRT1 is necessary for Akt activation. Furthermore,
a marked phosphorylation at Ser-83 of ASK1 (a specific Akt phos-
phorylation site) was present in Resv-treated keratinocytes indicat-
ing that Akt can inactivate ASK1 via SIRT1 pathway (Fig. 9B).
When SIRT1 inhibitor was added, ASK1 phosphorylation level at
Ser-83 greatly decreased.
Discussion
Vitiligo is an autoimmune pigmentary disorder characterized by the
loss of functional melanocytes from the involved epidermis. The aeti-
ology of vitiligo, which is considered to be multifactorial, is still a mat-
ter of debate. Attention has been addressed to keratinocytes, which
have been suggested to play a functional role in maintaining epider-
mal melanocytes [26].
Keratinocytes and melanocytes, being part of the epidermal-
melanin unit, are connected with each other and to the basement
membrane through adhesion molecules (E-cadherin, b-catenin
and integrins) [27, 28]. The detachment of melanocytes from
basal membrane and their migration to the upper layer of
epidermis could be because of a loss of dendricity of melano-
cytes or to an impairment of adhesion molecules [29]. In vitiligo
melanocytes, an abnormal morphology of dendrites, possibly
worsened by a high concentration of H2O2, has been suggested
[29].
There is strong evidence that a melanogenic cytokine network
able to regulate melanocyte function occurs between melanocytes
and other types of skin cells, including keratinocytes and fibroblasts
[30]. In fact, in co-culture systems constituted by keratinocytes and
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Fig. 5 (A) Confocal microscope analysis
and (B) flow cytometry analysis of casp-
ases-3, 8 and 9 activation in keratinocytes
from perilesional vitiligo skin in the pres-
ence of Resveratrol (Resv), Trolox or Res-
veratrol+SIRT1 inhibitor (Resv+SIRT1i).
The reported values (means  SD) are
representative of five independent experi-
ments, each performed in triplicate. *Sig-
nificant difference (P ≤ 0.05) versus
untreated perilesional keratinocytes.
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Fig. 6 (A) In untreated keratinocytes from
perilesional vitiligo skin and in keratino-
cytes from perilesional vitiligo skin after
48 hrs treatment of SIRT1 siRNA 100 nM,
SIRT1 protein expression was determined
by Western blot analysis. (B) To evaluate
the possible involvement of SIRT1 in oxi-
dative-mediated damage of vitiligo kerati-
nocytes, untreated and SIRT1 RNAi-
treated keratinocytes from healthy vitiligo
skin were challenged for 3 hrs with
500 lM H2O2. Reactive oxygen species
production, lipid peroxidation, caspase-3
activity and mitochondrial membrane
polarization were measured by flow
cytometry. These data confirm the key
role of SIRT1 in vitiligo. The reported val-
ues (means  SD) are representative of
three independent experiments, each per-
formed in triplicate. *Significant difference
(P ≤ 0.05) versus untreated perilesional
keratinocytes.
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melanocytes, keratinocyte-derived factors induce melanocyte prolifer-
ation and differentiation.
Keratinocyte-derived stem cell factor (SCF) [31, 32], endothelin-1
and granulocyte-macrophage colony-stimulating factor exert primary
roles, in melanocyte dendritogenesis, proliferation and melanogenesis
[33–36]. In addition, keratinocyte-derived basic fibroblastic growth
factor (b-FGF) stimulates the proliferation of epidermal melanocytes
[37]. The effects of the all above-mentioned cytokines and growth
factors are mediated by the binding with specific receptors localized
on the surface of melanocytes.
It has been demonstrated that protein and transcript levels of SCF
are actually reduced in depigmented lesions although there is some
Fig. 7MAPK phosphorylation in keratino-
cytes from perilesional vitiligo skin in the
presence of Resveratrol (Resv), Trolox or
Resveratrol+SIRT1 inhibitor (Resv+
SIRT1i). The reported values (means 
SD) are representative of four independent
experiments, each performed in triplicate.
*Significant difference (P ≤ 0.05) versus
untreated perilesional keratinocytes.
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debate about it [26, 38–41]. This finding is also confirmed by the evi-
dence that keratinocytes from vitiligo lesions appear to be more prone
to apoptosis [42] and unable to generate sufficient levels of SCF to
ensure melanocyte survival [39], compared to keratinocytes from
normally pigmented skin. The reduced expression of SCF likely results
from keratinocyte apoptosis and might be the cause of melanocyte
death.
In active vitiligo, perilesional keratinocytes display a vacuolar
appearance [43] suggesting that the impairment of keratinocyte func-
tion may be responsible for the loss of melanocytes in vivo, and may
also explain the defective melanocyte growth seen in vitro [44]. Hav-
ing said this, the molecular mechanisms that trigger keratinocyte
apoptosis are still poorly understood.
Among the mechanisms that have been evoked in the modulation
of cell stress response, the role of SIRT1 has been recently suggested
[25, 45] but its signalling and its possible involvement in vitiligo have
never been explored. Here, for the first time, we shed light on a new
SIRT1 signalling, which suggests a protective role in vitiligo keratino-
cytes.
We found that in keratinocytes from perilesional vitiligo skin oxi-
dative stress was markedly pronounced, consistent with our previous
results [4]. In contrast, keratinocytes treated with Resv and Trolox,
used at an equivalent antioxidant capacity, displayed much lower lev-
els of oxidative stress. Importantly, Resv displayed a greater protec-
tive effect than Trolox, an effect that is linked to SIRT1 activation. Also
in Resv-treated mitochondria of perilesional vitiligo cells superoxide
production, mitochondrial depolarization and impaired mPTP opening
were inhibited to a greater extent with respect to Trolox treatment. In
the presence of SIRT1 inhibitor all these effects were completely
reversed. Hence, our results suggest that, in the presence of Resv,
perilesional vitiligo keratinocytes are protected from cellular stress
and concurrently show the activation of SIRT1. Resv has been shown
to activate SIRT1, although it remains to be determined whether direct
interaction, or the involvement of intermediates, is required [46].
However, it must be considered that some of the protective effects of
Resv (e.g. its antioxidant properties) may be SIRT1-independent [47].
Our findings are in agreement with previous reports about a
decreased protective action of Resv in response to SIRT1 knockdown
[48] and with the lowering of mitochondrial ROS and cellular H2O2
production in cultured human coronary arterial endothelial cells (CAE-
Cs) following SIRT1 overexpression, thus recapitulating the effects of
Resv [48]. Moreover, SIRT1-induced upregulation of antioxidants and
downregulation of pro-apoptotic molecules, via FOXO activation and
reduction in oxidative stress, has been shown to protect transgenic
mice from IR-induced cardiac injury [49].
In our experimental model, following treatment with a SIRT1
inhibitor, Resv-induced protection against caspase activation was
completely repressed, suggesting that SIRT1 mediates the protective
effects of this compound. In this context it was recently shown that
SIRT1 promotes expression of protective molecules, including
MnSOD, Trx1 and Bcl-xL, while also down-regulating expression of
pro-apoptotic effectors (e.g. Bax) [49]. Moreover, SIRT1 can inhibit
apoptosis acting on p53 [45]. As p53 positively regulates Bax [50], it
is possible that SIRT1 may partly exert its protective effects by de-
acetylating and inhibiting p53. Indeed, we have previously demon-
strated a role for p53 in perilesional keratinocyte apoptosis and the
relevance of this pathway in cell death [16].
Another important result of this study is the relationship between
SIRT1 activation and MAPK signalling, an up-regulated pathway in
response to increased ROS production [51], which has been yet
shown to be markedly affected also in keratinocytes from perilesional
vitiligo skin [16]. Here, with specific inhibitors, we showed that JNK
and p38 kinases promote apoptosis, while ERK displays anti-
apoptotic effects.
Activation of JNK and p38 was found in keratinocytes from perile-
sional vitiligo skin. Resv treatment, but not Trolox or SIRT-1 inhibitor,
Fig. 8 The caspase-3 activity measured with flow cytometry analysis in
keratinocytes from perilesional vitiligo skin in the presence of specific
MAPK inhibitors. The reported values (means  SD) are representative
of four independent experiments, each performed in triplicate. *Signifi-
cant difference (P ≤ 0.05) versus untreated perilesional keratinocytes.
A
B
Fig. 9 (A) Phosphorylation and acetylation status of Akt immunoprecipi-
tated from phosphorylation in keratinocytes from perilesional vitiligo
skin in the presence of Resveratrol (Resv), Trolox or Resveratrol+SIRT1
inhibitor (Resv+SIRT1i). (B) Western blot analysis of ASK1 phosphory-
lation at Ser83 in keratinocytes. The reported images are representative
of four independent experiments.
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reduced phosphorylation to control levels. A recent study [13] found
that siRNA-mediated SIRT1 knockdown in cultured keratinocytes pro-
moted UV-induced JNK activation, and that this effect was reversed
by treatment with Resv, suggesting that SIRT1 protects cells against
UV-induced JNK activation. Previous reports conflict with our find-
ings, and showed that JNK alters SIRT1 function and localization,
while also stimulating its activation [52].
ERK has been shown to phosphorylate Thr202/Tyr204 in human
fibroblasts in response to SIRT1 transfection and treatment with Resv
[53]. How SIRT1 stimulates ERK phosphorylation remains to be
determined: however, a recent study showed that MAPK signalling
was suppressed by FK228, an HDAC inhibitor, which functions by up-
regulating Rap1 expression [54]. We found that, in perilesional vitiligo
cells, the p-ERK level was restored by Resv treatment and caspase-3
activity increased in the presence of ERK inhibitor, although this was
reversed by SIRT1 activation, suggesting that SIRT1 protects against
apoptosis. Indeed, our results indicate that ERK signalling partly
underlies the protective effects of SIRT1.
To investigate the molecular mechanisms by which SIRT1 regu-
lates MAPK pathways, we analysed the effects of SIRT1 on Akt (a ser-
ine/threonine kinase also known as protein kinase B, or PKB) and
ASK1 signalling. While p38 and JNK mediate cell apoptosis and skin-
damage processes, signals such as Akt negatively regulate this pro-
cess [55–57]. Under normal physiological conditions, Akt is activated
by growth factors, insulin, and DNA damage and is translocated from
the cell membrane to its target genes, supporting the complex regula-
tory network [58]. Among its various cellular functions, there is
extensive evidence that Akt plays a central role in regulating growth
factor-mediated cell survival and blocking apoptosis [59]. Activated
Akt relays its survival signals in a number of ways, including via phos-
phorylation and inactivation of pro-apoptotic factors such as ASK1
[60]. It has been shown that an active form of Akt blocks apoptosis
via inhibition of AIF nuclear translocation [61] and that Akt directly
phosphorylates human caspase-9, resulting in its inactivation [62].
Suppression of Akt leads to activation of the BCL-2 homology-3
domain-only proteins BIM and BAD, which in turn mediate the release
of cytochrome c. Several lines of evidence have shown that Akt plays
an essential role in protecting keratinocytes against UVB-induced
apoptosis, by abolishing cytochrome c release and activation of casp-
ases-3, -8 and -9 [57]. Furthermore, anti-apoptotic signals leading to
the suppression of UVB-induced apoptosis by various factors have
been shown to be mainly mediated through Akt activation [63]. In
patients with vitiligo, Akt1 phosphorylation is reduced [64] and
impaired PI3K/Akt activation is involved in keratinocyte apoptosis
[65].
Many of the cellular processes regulated by Akt are also modu-
lated by SIRT1: indeed, SIRT1 has been used to treat metabolic disor-
ders characterized by aberrant Akt signalling [66].
In this study, we found that in perilesional vitiligo keratinocytes
Akt phosphorylation levels increased in Resv-treated cells. This
was associated with deacetylation of Akt, suggesting that SIRT1-
mediated deacetylation and activation of Akt protects perilesional
vitiligo keratinocytes from cell death. SIRT1-mediated deacetylation
of Akt is required for its activation as it has been suggested
recently by our and other groups[25, 67], who showed that Akt
phosphorylation decreased in the presence of a SIRT1 inhibitor,
confirming that SIRT1 activity is required for Akt activation. Apop-
tosis signal-regulating kinase-1 is a MAPK kinase kinase (MAP-
KKK) family member [68], which is activated in response to
oxidative stress, and other stimuli [69, 70]. It is activated via dis-
tinct mechanisms and relays those signals to stress-activated MAP
kinases, such as JNK and p38 [71, 72]. Overexpression or hyper-
activation of ASK1 causes mitochondria-dependent apoptosis, via
cytochrome c release and activation of caspase-3/9 in various cell
types [73, 74]. Moreover, it is known that ASK1-mediated JNK
activation phosphorylates Bcl-2, leading to a reduction in its anti-
apoptotic activity [75]. However, the detailed molecular mecha-
nisms that link mitochondria-dependent apoptosis and ASK1-p38/
JNK activation remain unknown. In contrast, overexpression of
ASK1 induces not only apoptosis but also cell differentiation and
survival, depending on the cell type; for example, ASK1 induces
neurite outgrowth in PC12 cells and keratinocyte differentiation via
p38 pathway activation [76, 77]. The mechanism that links ROS to
the activation of p38 MAPK and JNK pathways involves regulation
of the thioredoxin-ASK1 complex [(SH2)Trx-ASK1]. This complex
inhibits the activity of ASK1 and, in turn, its activation of down-
stream p38 and JNK MAPK pathways [78]. In keratinocytes from
perilesional vitiligo skin a decreased phosphorylation of ASK1 at
Ser-83 and a concomitant marked increase in JNK and p38 phos-
phorylation were observed. We also found that ASK1 phosphoryla-
tion at Ser-83 returned to control levels following treatment with
Resv. Reports suggest that H2O2 is responsible for decreased Akt
and ASK1 (Ser-83) phosphorylation, as well as increased ASK1
phosphorylation at Thr-845. However, the H2O2 responsiveness of
an ASK1 point mutant, ASK1S83A, was largely unaffected by Akt,
suggesting a specific phosphorylation event in Akt-mediated inhibi-
tion [60].
To our knowledge, this is the first study to demonstrate the pro-
tective role of SIRT1 in vitiligo and its underlying mechanism. SIRT1
regulates MAPK signalling via Akt-ASK1 and down-regulates pro-
apoptotic molecules, leading to decreased oxidative stress/apoptotic
cell death in perilesional vitiligo keratinocytes. We therefore
propose SIRT1 activation as a novel way of protecting perilesional
vitiligo keratinocytes from damage. Pharmacological manipulation of
sirtuin activity, which began with the use of Resv, has now extended
to a variety of newer agents that appear to have greater specificity.
Some of these agents are already in human clinical trials [79] and
could be used as a therapeutical tool to protect against vitiligo
progression.
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